Report: Valeant in talks to buy Egypt's Amoun for up to $800M

Valeant's ($VRX) next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun. That company could fetch between $700 million and $800 million, Bloomberg's sources say, though the talks are still in the early stages. Amoun would be Valeant's third conquest since losing out on longtime target Allergan, following acquisitions of Salix and the assets of bankrupt biotech Dendreon. If a transaction between the pair doesn't go through, though, Amoun could go the IPO route, Bloomberg reports. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.